InsiderTrades

Form 4 for LONA LeonaBio, Inc.

Accepted 2025-07-02 00:00:00 ET · period of report 2025-06-30 · accession 0001415889-25-019070 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-07-02 2025-07-01 LONA CHURCH KEVIN CSO S - Sale+OE $0.29 -8,526 168.9K -5% -$2,473
D 2025-07-02 2025-05-19 LONA CHURCH KEVIN CSO A - Grant $0.23 +10.0K 140.8K +8% +$2,300
D 2025-07-02 2025-06-30 LONA CHURCH KEVIN CSO M - OptEx $0.00 +36.7K 177.4K +26% $0
D 2025-07-02 2025-06-30 LONA CHURCH KEVIN CSO M - OptEx $0.00 -36.7K 36.7K -50% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-07-01 S D 8,526 $0.29 168,901 D — — (F5) The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $0.2854 to $0.3031, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
2 Common Common Stock 2025-05-19 A A 10,000 $0.23 140,761 D — — (F1) The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"),for the ESPP Purchase Period (as defined in the ESPP) of November 18, 2024 through May 19, 2025. This transaction is exempt under Rule 16b-3(c). (F2) The Purchase Period ended March 19, 2025 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began November 18, 2024. (F3) In accordance with the ESPP, these shares were purchased based on 85% of the closing price on May 19, 2025.
3 Common Common Stock 2025-06-30 M A 36,666 $0.00 177,427 D — —
4 Derivative Restricted Stock Units 2025-06-30 M D 36,666 $0.00 36,667 D — · — to — 36,666 Common Stock (F6) RSUs convert into common stock on a one-for-one basis. (F7) Each RSU represents a contingent right to receive one (1) share of Issuer's common stock. (F8) On October 1, 2024, the reporting person was granted 110,000 RSUs. One-third (1/3rd) of the RSUs vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the applicable vesting dates.